

# The 11<sup>th</sup> Bioscience Economy Conference

October 19, 2005  
Geneva – Switzerland

October 20, 2005  
Milano – Italy



## PRELIMINARY PROGRAM

### October 19, 2005 – Hotel Warwick – Geneva

**09:00** Registration & Welcome  
**09:15** Bradley Pharmaceuticals, Inc.  
**10:00** Isotechnika, Inc.  
**10:45** Coffee break  
**11:15** Biophan Technologies, Inc.  
**12:00** Buffet & Networking Lunch  
**12:45** Adaltis, Inc.  
**13:30** Conclusive Remarks

### October 20, 2005 – Assolombarda - Milano

**08:45** Registration & Welcome  
**09:15** Bradley Pharmaceuticals, Inc.  
**09:50** Aastrom Biosciences, Inc.  
**10:25** Adaltis, Inc.  
**11:00** Biophan Technologies, Inc.  
**11:35** Isotechnika, Inc.  
**12:10** Nicox, S.A.  
**12:30** Round table  
**13:00** Lunch

#### REGISTRATION INFORMATION

**Location:** **October 19, Geneva, Switzerland**  
Hotel Warwick, 14 rue de Lausanne - Salon Mont-Blanc  
**October 20, Milano, Italy**  
Assolombarda, Via Pantano, 9 – Auditorium Gio Ponti

**Language:** **English**

**Admission:** **By invitation, free**

**Registration:** **Fax the registration form or send an e-mail to:**  
**Dr. M. Bottaro**      **Fax: 0041 91 611 9199**  
**E-mail: marco@capitalife.com**

## PARTICIPANTS: SHORT COMPANY PROFILE

### ■ AASTROM BIOSCIENCES, INC.

Aastrom (Nasdaq: ASTM) is developing patient-specific cell products for the repair or regeneration of human tissues. Aastrom's strategic position in the tissue regeneration sector is enabled by its proprietary Tissue Repair Cells (TRCs), a mix of bone marrow-derived adult stem and progenitor cells. TRCs are manufactured in the Company's proprietary AastromReplicell® System, an industry-unique, automated cell production platform. In a 12-day production cycle, clinical quantities of Aastrom's TRCs are manufactured from a small aspirate of bone marrow collected from the patient in an outpatient setting. TRC cell products are in active clinic trials and are being developed for the following therapeutic areas: severe bone fractures (US: Phase I/II; EU: Proof of Concept trial), ischemic vascular disease (EU: Phase I/II), jaw reconstruction (EU: Proof of Concept trial) and spine fusion (IND submitted to the FDA). For more information, please visit: [www.aastrom.com](http://www.aastrom.com)

### ■ ADALTIS, INC.

Adaltis (TSX: ADS.TO) is an in-vitro diagnostic company with headquarters in Montreal and offices in China, Hong Kong, Italy, and Germany. Based on the long standing expertise in infectious diseases, fertility and thyroid diagnostics, Adaltis develops, manufactures and markets automated systems and reagents to detect viral infections, diagnose immune disorders and measure human hormone responses. Through its China based operations, Adaltis manufactures high-quality products in a low-cost GMP environment in order to service existing markets in Europe, while providing a platform to penetrate the high-growth Chinese in vitro diagnostic market.

For more information, please visit: [www.adaltis.com](http://www.adaltis.com)

### ■ BIOPHAN TECHNOLOGIES, INC.

Biophan (OTCBB: BIPH.OB) develops competitively advantaged technologies for the medical device industry, covering several areas, including:

- Safety and image compatibility of devices when imaged with Magnetic Resonance Imaging (MRI), including stents imageable under MRI
- A ceramic motor (the Squiggle™ motor) that is MRI safe and compatible
- A biothermal power supply that generates electricity from body heat
- Novel drug delivery technology based on nanomaterials

Biophan recently closed a \$5.75 million equity and licensing agreement with Boston Scientific (NYSE: BSX). Biophan's management team includes former executives of J&J and Angiotech.

For more information, please visit: [www.biophan.com](http://www.biophan.com)

### ■ BRADLEY PHARMACEUTICALS, INC.

Founded in 1985, Bradley Pharmaceuticals, Inc., is a specialty pharmaceutical company providing dermatology and podiatry brands through its Doak Dermatologics subsidiary and gastroenterology brands through the Kenwood Therapeutics division. Bradley's strategy, expressed as "Acquire, Enhance, Grow," is to Acquire brands from larger pharmaceutical companies, Enhance these brands with line extensions and improved formulations, and Grow these products through advertising and selling activities to optimize life cycle management both domestically and in 38 international markets. In 1991, Bradley became a publicly traded company on the NASDAQ exchange, and made the transition to the NYSE in May 2003.

For more information, please visit: [www.bradpharm.com](http://www.bradpharm.com)

### ■ ISOTECHNIKA, INC.

Isoteknika (TSX: ISA.TO) is an international biopharmaceutical company headquartered in Edmonton, Alberta – Canada. The company is focused on the discovery and development of novel immunosuppressive therapeutics that are safer than currently available treatments. Isoteknika's lead compound, ISA247 is an immunosuppressant currently being investigated as a treatment for moderate to severe psoriasis (Phase III) and for use in the prevention of rejection in kidney transplantation (Phase IIb).

For more information, please visit: [www.isoteknika.com](http://www.isoteknika.com)

### ■ NICOX S.A.

NicOx (Bloomberg: COX.FP, Reuters: NCOX.LN), headquartered in Sophia-Antipolis, France, is a public company listed on the Euronext Paris (segment: Next Economy). NicOx is an emerging pharmaceutical company involved in the research and development of nitric oxide-donating drugs with superior efficacy and safety profiles in the inflammation, pain and cardiovascular therapeutic areas. NicOx seeks to commercialize its products through partnerships and co-development agreements where it maintains future marketing rights for specialist products.

For more information, please visit: [www.nicox.com](http://www.nicox.com)

## THE 11<sup>TH</sup> BIOSCIENCE ECONOMY CONFERENCE IS SPONSORED BY



**POLARIS**  
PARCO SCIENTIFICO  
E TECNOLOGICO  
DELLA SARDEGNA

## AND ORGANIZED BY



Capitalife



Siena  
Financial  
Services



## INSTITUTIONAL PARTNERS



Canada-Italy Business Council - Consiglio Commerciale Italo-canadese - Conseil commercial Canada-Italie



## MEDIA PARTNERS



**BioCentury®**

FOR INFORMATION ON THE CONFERENCE PLEASE CONTACT:  
**DR. M. BOTTARO, TEL. +39 348 0456 709; e-mail: marco@capitalife.com**